Acute coronary syndromes: 2. Antiplatelet agents.
Therapies with novel antiplatelet agents and anticoagulants are the focus of current research. When used separately or in combination, these agents prevent generation of thrombin by activated platelets. The new therapies, in conjunction with judicious use of fibrinolytic drugs and mechanical interventions, are revolutionizing the management of patients with acute coronary syndromes.
Schneider
D J
DJ
Department of Medicine, University of Vermont School of Medicine, Burlington, USA.
Tracy
P B
PB
Sobel
B E
BE
D000077284:Abciximab; D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy* / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000145:classification / Q000627:therapeutic use*; D011322:Primary Prevention
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D000077284:Abciximab